MedWellAI Increases Authorized Series B Convertible Preferred Stock by 50%
MWAI sits 85% above its 52-week low of $0.2.
Summary
MedWellAI, Inc. increased its authorized Series B Convertible Preferred Stock by 50% to 1.5 million shares, a move likely aimed at enabling future capital raises amidst financial distress.
Key Events · Financing and Capital Events · MWAI
-
Increased Authorized Preferred Stock
MedWellAI, Inc. amended its Certificate of Designation to increase the authorized Series B Convertible Preferred Stock from 1,000,000 to 1,500,000 shares.
-
Shareholder Approval
The amendment was approved by holders of 90% of the outstanding Series B Preferred Stock on April 13, 2026.
-
Enables Future Financing
This authorization provides the company with additional capacity to issue preferred shares, likely in preparation for future capital raises to address its financial challenges, including a previously reported going concern warning.
Analysis · MWAI · Crypto Assets
MedWellAI, Inc. has increased its authorized Series B Convertible Preferred Stock by 50%, from 1,000,000 to 1,500,000 shares. This action, approved by a supermajority of existing preferred shareholders, is a preparatory step for potential future capital raises. Given the company's previously disclosed significant working capital deficit and going concern warning, this authorization provides necessary flexibility to secure financing, but also signals potential significant dilution for common shareholders if these preferred shares are issued and subsequently converted.
At the time of this filing, MWAI was trading at $0.37 on OTC in the Crypto Assets sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.20 to $1.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.